GlassScriptPhysician profile
Katherine Garcia
NPI 1417484221
$5,464.67
in general payments reported to CMS, 2019-2025
42 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $1,285 · 2024: $2,833 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.57 |
| Education | $101.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $603.37 | 2023-2025 | |
| Abbvie INC. | $534.43 | 2023-2025 | |
| Janssen Biotech, INC. | $452.17 | 2023-2025 | Darzalex, Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $308.77 | 2023-2025 | Enhertu, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $256.14 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $206.04 | 2023-2025 | |
| Mirati Therapeutics, INC. | $199.82 | 2023-2024 | Krazati |
| Seagen INC. | $182.99 | 2021-2023 | |
| Genentech USA, INC. | $178.47 | 2023-2024 | Tecentriq, Alecensa, Phesgo |
| Exelixis INC. | $170.75 | 2023-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $161.48 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Incyte Corporation | $155.69 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Merck Sharp & Dohme LLC | $154.90 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Jazz Pharmaceuticals INC. | $154.47 | 2023-2025 | |
| Celgene Corporation | $149.78 | 2024-2025 | Reblozyl, Opdivo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $140.76 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $132.22 | 2023-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $107.12 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $105.34 | 2023-2024 | Libtayo |
| Array Biopharma INC | $102.54 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Lilly USA, LLC | $90.41 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $85.08 | 2023-2024 | |
| Genzyme Corporation | $73.82 | 2023-2024 | |
| Astellas Pharma US INC | $72.76 | 2024-2025 | Padcev |
| Aveo Pharmaceuticals, INC. | $65.49 | 2024-2025 | |
| Sobi, INC | $63.44 | 2023-2025 | |
| Coherus Oncology, INC. | $60.10 | 2023-2025 | Loqtorzi |
| Glaxosmithkline, LLC. | $59.71 | 2024-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $58.18 | 2023 | Vonvendi, Ninlaro, Alunbrig |
| Adc Therapeutics America, INC. | $50.79 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $47.52 | 2023-2024 | Precisetumor, Myrisk |
| Pharmaessentia USA Corporation | $46.69 | 2023 | Besremi |
| Amgen INC. | $44.49 | 2023 | Kyprolis, Lumakras |
| Sumitomo Pharma America, INC. | $28.56 | 2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $26.06 | 2023 | Epkinly |
| Stemline Therapeutics INC. | $24.57 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $22.08 | 2024 | Onivyde |
| Progenics Pharmaceuticals, INC. | $20.30 | 2023 | Pylarify |
| Emd Serono, INC. | $20.15 | 2024 | |
| Servier Pharmaceuticals LLC | $16.97 | 2024 | |
| Agios Pharmaceuticals, INC. | $15.90 | 2025 | Pyrukynd |
| Tempus Ai, INC | $14.35 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.